MedPath

Hypericin

Generic Name
Hypericin
Drug Type
Small Molecule
Chemical Formula
C30H16O8
CAS Number
548-04-9
Unique Ingredient Identifier
7V2F1075HD
Background

Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.

Clinical Trials
Related News

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Phase 3
Recruiting
Conditions
Mycosis Fungoides
Cutaneous T Cell Lymphoma
CTCL/ Mycosis Fungoides
CTCL
Interventions
Drug: Placebo
First Posted Date
2024-06-24
Last Posted Date
2025-05-13
Lead Sponsor
Soligenix
Target Recruit Count
80
Registration Number
NCT06470451
Locations
🇺🇸

Medical Dermatology Specialists, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic, Scottsdale, Arizona, United States

🇺🇸

Therapeutics Clinical Research, San Diego, California, United States

and more 13 locations

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Phase 2
Completed
Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
First Posted Date
2023-11-28
Last Posted Date
2024-07-03
Lead Sponsor
Soligenix
Target Recruit Count
10
Registration Number
NCT06149247
Locations
🇺🇸

Rochester Skin Lymphoma Medical Group, Fairport, New York, United States

Treatment of Mycosis Fungoides with Hypericin Ointment and Visible Light

Phase 2
Recruiting
Conditions
Cutaneous T Cell Lymphoma
Mycosis Fungoides
Interventions
Other: Visible Light
First Posted Date
2023-05-24
Last Posted Date
2025-01-22
Lead Sponsor
Ellen Kim, MD
Target Recruit Count
20
Registration Number
NCT05872854
Locations
🇺🇸

Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

Topical SGX302 for Mild-to-Moderate Psoriasis

Phase 2
Recruiting
Conditions
Plaque Psoriasis
Psoriasis
Psoriasis Vulgaris
Interventions
Drug: Placebo
First Posted Date
2022-07-01
Last Posted Date
2024-11-27
Lead Sponsor
Soligenix
Target Recruit Count
47
Registration Number
NCT05442190
Locations
🇺🇸

Therapeutics Clinical Research, San Diego, California, United States

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Phase 2
Completed
Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
First Posted Date
2022-05-19
Last Posted Date
2023-06-07
Lead Sponsor
Soligenix
Target Recruit Count
9
Registration Number
NCT05380635
Locations
🇺🇸

Rochester Skin Lymphoma Medical Group, Fairport, New York, United States

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT00000792
Locations
🇺🇸

Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

🇺🇸

NY Univ. HIV/AIDS CRS, New York, New York, United States

A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
32
Registration Number
NCT00000645
Locations
🇺🇸

Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

🇺🇸

University of Minnesota, ACTU, Minneapolis, Minnesota, United States

🇺🇸

NY Univ. HIV/AIDS CRS, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy